The Rapidly Shifting Ketamine Landscape in the US
Samuel T. Wilkinson, Joseph J Palamar, Gerard Sanacora
JAMA Psychiatry January 3, 2024 DOI: 10.1001/jamapsychiatry.2023.4945 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Ketamine Esketamine |
| Keywords | Recreational drug Recreational use |
| Citations | 41 |
| Key points | Ketamine is increasingly used both medically and recreationally, necessitating more research and surveillance. |
Abstract
This Viewpoint discusses changes in the use of ketamine as a medical therapeutic and a recreational substance, the potential risks of use, and the need for increased research and surveillance.
Citations in the library
Cited by 25
- At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data. Journal of Affective Disorders September 15, 2024
- Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022. Journal of Affective Disorders March 15, 2025
- State Cannabis and Psychedelic Legislation and Microdosing Interest in the US. JAMA Health Forum June 7, 2024
- Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression JAMA Psychiatry October 22, 2025
- A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists. Journal of Affective Disorders October 15, 2024
and 20 more in the library
Cites 6
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders JAMA Psychiatry March 1, 2017
- Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial British medical journal February 2, 2022
- Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study Neuropsychopharmacology May 12, 2023
- Characteristics of poisonings involving ketamine in the United States, 2019-2021. Journal of Psychopharmacology August 2023
- Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. New England Journal of Medicine May 22, 2019
and 1 more in the library